There's more to Australian biotech than just CSL: the opportunities to watch

LiveWire

2024-12-16

Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren (ASX: NEU) and Telix (ASX: TLX...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2491503738"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491503738\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2491503738?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-16 04:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491503738","market":"us","top_or_hot":-1,"title":"There's more to Australian biotech than just CSL: the opportunities to watch","media":"LiveWire","content":"<html><body><div>\n<p>Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren (ASX: NEU) and Telix (ASX: TLX...</p>\n<a href=\"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch\">网页链接</a>\n</div>\n</body></html>","source":"livewire_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>There's more to Australian biotech than just CSL: the opportunities to watch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThere's more to Australian biotech than just CSL: the opportunities to watch\n</h2>\n<h4 class=\"meta\">\n\n\n2024-12-16 04:09 GMT+8   <a href=\"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch\"><strong>LiveWire</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren (ASX: NEU) and Telix (ASX: TLX...</p>\n<a href=\"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGXZ23171101.USD","symbol_name":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","start_time":0,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","article_id":"2491503738","we_media_id":null,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","pubTimestamp":1734293355,"columns":[],"sourceInfo":{"source_id":"livewire_stock","name":"Livewire Markets"},"weMediaInfo":null,"summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","collect":0,"end_time":0,"defaultTopTitle":"livewiremarkets.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK7501":"新冠治疗股","BK7096":"制药","OPT.AU":"OPTHEA LTD","CSL":"卡莱尔伙伴","BK4086":"建筑产品","BK7502":"大麻概念","TLX.AU":"TELIX PHARMACEUTICALS LTD","DXB.AU":"DIMERIX LTD","SNT.AU":"Syntara Ltd","NEU.AU":"NEUREN PHARMACEUTICALS LTD","CVB.AU":"CurveBeam AI Limited","CSL.AU":"CSL LIMITED","BK7508":"医药生物股","BOT.AU":"BOTANIX PHARMACEUTICALS LTD","IMM.AU":"IMMUTEP LTD","BK7511":"ESG概念","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","XAO.AU":"标普/澳交所 普通股指数","BK7007":"医疗保健设备","XJO.AU":"标普/澳交所 200指数","BK7067":"生物科技","XKO.AU":"标普/澳交所 300指数"},"translate_title":"澳大利亚生物技术不仅仅是CSL：值得关注的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1,"XKO.AU":1,"XJO.AU":1,"XAO.AU":1,"TLX.AU":1,"SNT.AU":1,"OPT.AU":1,"NEU.AU":1,"DXB.AU":1,"CVB.AU":1,"CSL.AU":1,"CSL":1,"BOT.AU":1},"content_text":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren (ASX: NEU) and Telix (ASX: TLX) delivering FDA approved products and becoming profitable. Botanix (ASX: BOT) has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility. \nSeveral other companies including Opthea (ASX: OPT), Immutep (ASX: IMM) and Dimerix (ASX: DXB) are progressing through Phase 3 trials, while Syntara (ASX: SNT) is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.\nOverseas macro environment \nOn the macroeconomic front, the picture is less clear. The US FDA may undergo significant structural changes in 2025 which could bring changes that impact drug and device development all over the world. The changes could be huge such as splitting up the agency to remove ‘Food’ and having the FDA focus exclusively on healthcare.\nThere are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development. \nWe are focused on ensuring our portfolio companies are well funded, focused on high quality clinical trials that generate actionable data, while carefully managing cash reserves.\nBiden’s Inflation Reduction Act (IRA) granted US Medicare the ability to negotiate drug prices directly with pharmaceutical companies – a policy strongly opposed by the Republicans who may seek to reverse it. This could deliver much needed positive sentiment in the sector.\nCapital market dynamics\nOn the capital market front, this uncertainty around the future direction of the FDA has seen healthcare lag when compared with other sectors. \n\n\n\n\n\n\n\n\n\nSource: NASDAQ (IXHC & COMP)\nWe still have not seen a pickup in IPO activity, with the window for new offerings unlikely to reopen until greater regulatory clarity emerges. \nThe market has bifurcated, favouring later stage companies securing significant capital to fund pivotal trials, while early stage firms struggle to attract funding. \nAnecdotal evidence we have seen suggests that it is easier to raise $100m for a Phase 3 trial than $10m for preclinical research. \nBig Pharma continues to approach acquisitions cautiously, prioritising companies at Phase 3 stage or with FDA-approved drugs over early stage ‘platform’ technologies – a shift from the acquisition trends seen in 2020/21. With over US$150b in revenue expected to be lost to patent expirations by 2028, we anticipate sustained M&A activity focused on filling these gaps\nAustralia’s stable regulatory environment\nIn contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive of the R&D ecosystem in Australia, recently announcing a review of ‘Australia’s research and development performance,’ a signal to its commitment to fostering innovation. \nAs discussed earlier, this stable environment has helped nurture our maturing biotech ecosystem and is delivering more companies reaching advanced stages of development. We are seeing more and more biotech’s at Phase 2 stage and medical device companies approaching regulatory approvals. However, Australia’s venture capital ecosystem remains underdeveloped, posing a challenge for adequately funding these later-stage opportunities.\nOutlook for 2025\nWe remain positive about the catalysts ahead for our portfolio companies. We believe that both Syntara (ASX: SNT) and CurveBeam AI (ASX: CVB), our two listed investments, are positioned well for strong developments in 2025. Syntara’s Phase 2 trial results were announced recently and could lead to a Phase 3 trial which is an important milestone. \n\n\n\n\n\n\n\n\n\n1 year performance of Syntara. Source: Market Index, 12 December 2024\nMeanwhile, CurveBeam AI continues its efforts to innovate the orthopaedic imaging landscape with its HiRise bilateral weight-bearing CT system.  These are good examples in the local market and we continue to work to identify other opportunities in the Australian venture capital ecosystem. \n\n\n\n\n\n\n\n\n\n1 year performance of CurveBeam AI. Source: Market Index, 12 December 2024\nAs the local and global biotech sectors evolve, we remain focused on navigating uncertainty and capitalising on opportunities to deliver meaningful outcomes for our portfolio and stakeholders.\n\n\n\nManaged Fund\nKP Rx Healthcare Opportunities Fund\nAlternative Assets\n\n\nView\n\n\n\n\n\n \n\n\nNever miss an update\n\n    Enjoy this wire? Hit the ‘like’ button to let us know. \n    Stay up to date with my current content by \n    following me below and you’ll be notified every time I post a wire","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}